Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium
September 13 2022 - 8:00AM
Business Wire
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing
and commercializing software-based medicines called prescription
digital therapeutics (PDTs), today announced the company will
participate in the LifeSci Partners HealthTech Symposium on
September 20, 2022. Corey McCann, M.D., Ph.D., President and CEO,
will participate in a virtual fireside chat at 12:30 p.m. ET.
A live audio webcast of the presentation can be accessed by
clicking here and will be made available in the Investors section
of Pear’s website at www.peartherapeutics.com. A replay of the
webcast will be available on Pear’s website for up to 30 days
following the live presentation.
About Pear Therapeutics Pear Therapeutics, Inc., which is
traded on Nasdaq as PEAR, is the parent company of Pear
Therapeutics (US), Inc. Pear is the leader in developing and
commercializing software-based medicines, called prescription
digital therapeutics (PDTs). Pear aims to redefine care through the
widespread use of clinically validated software-based therapeutics
to provide better outcomes for patients, smarter engagement and
tracking tools for clinicians, and cost-effective solutions for
payers. Pear has the first end-to-end platform to discover,
develop, and deliver PDTs to patients and a pipeline of products
and product candidates across therapeutic areas., including the
first three PDTs with disease treatment claims from the FDA. Pear’s
product, reSET®, for the treatment of substance use disorder, was
the first PDT to receive marketing authorization from the FDA to
treat disease. Pear’s second product, reSET-O®, for the treatment
of opioid use disorder, was the first PDT to receive Breakthrough
Designation. Pear’s third product, Somryst® for the treatment of
chronic insomnia, was the first PDT submitted through FDA’s
traditional 510(k) pathway while simultaneously reviewed through
FDA’s Software Precertification Pilot Program. For more
information, visit Pear at www.peartherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220913005256/en/
Media and Investors: Meara Murphy Senior Director,
Corporate Communications meara.murphy@peartherapeutics.com
Pear Therapeutics (NASDAQ:PEAR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pear Therapeutics (NASDAQ:PEAR)
Historical Stock Chart
From Jul 2023 to Jul 2024